A Phase I Study of the Safety, Pharmacokinetics, and Anti-Tumor Activity of TH-302 in Patients With Advanced Solid Tumors
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Glen Weiss, MD
Translational Drug Development
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
7 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Mayo Clinic Arizona
Scottsdale, Arizona, United States
- Tgen Drug Development Services
Scottsdale, Arizona, United States
- St. Mary'S Medical Center
San Francisco, California, United States
- Indiana University Simon Cancer Center
Indianapolis, Indiana, United States
- Mayo Clinic Rochester
Rochester, Minnesota, United States
- Sarah Cannon Research Institute
Nashville, Tennessee, United States
- Mary Crowley Cancer Research Centers
Dallas, Texas, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 30 Jun 2007
- Primary completion
- 31 Dec 2011
- Completion
- 30 Jun 2012
- Last update posted
- 27 Jul 2012
- Registered enrollment
- 129
- Registry id
- NCT00495144
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.